TCR Therapy Pipeline Insight 2025: Targeting Intracellular Tumor Antigens with Unmatched Specificity | DelveInsight

T-cell receptor (TCR) therapy represents a next-generation cell-based immunotherapy that unlocks access to intracellular tumor antigens presented via MHC molecules, overcoming limitations of conventional CAR-T therapies. TCR therapies are gaining momentum, particularly for solid tumors, by enabling antigen-specific immune responses that are tailored to a patient's unique HLA profile. DelveInsight's "TCR Therapy - Pipeline Insight, 2025" analyzes over 55 pipeline candidates under active clinical development, focusing on high-value targets such as NY-ESO-1, MAGE-A4, KRAS, and TP53 mutations.

Leading biotech and pharma players, including Immunocore, Guangdong Xiangxue Precision Medical Technology Co., Ltd, Neogene Therapeutics, TScan Therapeutics, and others, are driving innovation using affinity-enhanced TCRs, ImmTACs (TCR-based bispecifics), and CRISPR-engineered TCR-T platforms. These therapies are in clinical trials across difficult-to-treat solid tumors such as synovial sarcoma, NSCLC, melanoma, and ovarian cancer. Emerging modalities like off-the-shelf allogeneic TCR-Ts and TCR+checkpoint inhibitor combinations are being explored to improve tumor infiltration, persistence, and immune modulation.

DelveInsight's report evaluates key clinical progress, biomarker strategies, safety challenges (e.g., off-target toxicity), and regulatory milestones. As more precision-driven therapies progress into mid-to-late-stage trials, TCR therapy is increasingly positioned as a viable alternative in the personalized immuno-oncology space, aiming not just for response but for durable remission in patients with high unmet need.

Interested in learning more about the current treatment landscape and the key drivers shaping the TCR Therapy pipeline? Click here: https://www.delveinsight.com/report-store/tcr-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the TCR Therapy Pipeline Report
• DelveInsight's TCR Therapy pipeline analysis depicts a strong space with 50+ active players working to develop 55+ pipeline drugs for TCR Therapy treatment.
• The leading TCR Therapy companies include Immunocore, Guangdong Xiangxue Precision Medical Technology Co., Ltd, Neogene Therapeutics, TScan Therapeutics, SCG Cell Therapy, Triumvira, JW Therapeutics, Immatics, China Immunotech, T-Cure, 2seventy bio, and others are evaluating their lead assets to improve the TCR Therapy treatment landscape.
• Key TCR Therapy pipeline therapies in various stages of development include Brenetafusp, TAEST 16001, NT-175, TSC 101, SCG 162, TAC01 HER2, ECT204, TSC-100, IMA201, CMV TCR-T, 820 TCR, MAGE-A4 TCR program, and others.
• In February 2025, Lion TCR received FDA clearance to begin a Phase 2 international trial for its mRNA-based TCR-T cell therapy, Liocyx-M004, targeting hepatocellular carcinoma (HCC).
• In August 2024, the FDA approved afamitresgene autoleucel (afami-cel, branded as Tecelra) as the first TCR therapy for metastatic synovial sarcoma.
• In August 2024, Thermo Fisher's SeCoreTM CDx HLA A Sequencing System received 510(k) FDA clearance as a companion diagnostic for Tecelra in HLA-A*02-positive patients with MAGE-A4-expressing tumors.

Request a sample and discover the recent breakthroughs happening in the TCR Therapy pipeline landscape at https://www.delveinsight.com/report-store/tcr-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

TCR Therapy Overview
T-cell receptor (TCR) therapy is an advanced form of adoptive cell therapy designed to treat cancer by harnessing the body's immune system. Unlike CAR-T therapy, which targets surface antigens, TCR therapy can recognize and target intracellular tumor-associated antigens presented by MHC (major histocompatibility complex) molecules. This allows TCR therapies to address a wider range of cancers, including solid tumors.

The process involves isolating a patient's T cells, genetically modifying them to express a specific TCR that recognizes cancer antigens, expanding them in a lab, and then reinfusing them into the patient. TCR therapies are particularly promising for cancers expressing known antigens like NY-ESO-1 and MAGE-A4, and several candidates are in clinical trials or recently approved (e.g., afamitresgene autoleucel/Tecelra for synovial sarcoma). While still emerging, TCR therapies represent a major advancement in personalized oncology and immunotherapy.

Find out more about TCR Therapy medication at https://www.delveinsight.com/report-store/tcr-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

TCR Therapy Treatment Analysis: Drug Profile
Brenetafusp: Immunocore
Brenetafusp, also known as IMC-F106C, is an ImmTAC (Immune mobilizing monoclonal T-cell receptor Against Cancer) therapy targeting the PRAME antigen in patients with HLA-A02, found in about 40% of Western populations. To expand its reach, Immunocore is also developing IMC-T119C, targeting PRAME presented by HLA-A24-an HLA type present in roughly 60% of Japanese individuals and 15-20% of Western populations. Brenetafusp is currently in Phase III trials for the first-line treatment of advanced cutaneous melanoma.

Pemvidutide: Altimmune
Pemvidutide (formerly ALT-801) is a dual GLP-1/glucagon receptor agonist being developed for obesity and nonalcoholic steatohepatitis (NASH). It mimics the effects of diet and exercise by reducing appetite (via GLP-1) and increasing energy expenditure (via glucagon). The drug also promotes fat breakdown and may improve insulin resistance. Formulated with the proprietary EuPortTM technology to allow weekly dosing and enhanced tolerability, pemvidutide showed strong reductions in body weight, liver fat, and lipids in Phase I studies. It is currently in Phase II trials for NASH.

Learn more about the novel and emerging TCR Therapy pipeline therapies at https://www.delveinsight.com/report-store/tcr-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

TCR Therapy Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the TCR Therapy Pipeline Report
• Coverage: Global
• Key TCR Therapy Companies: Immunocore, Guangdong Xiangxue Precision Medical Technology Co., Ltd, Neogene Therapeutics, TScan Therapeutics, SCG Cell Therapy, Triumvira, JW Therapeutics, Immatics, China Immunotech, T-Cure, 2seventy bio, and others.
• Key TCR Therapy Pipeline Therapies: Brenetafusp, TAEST 16001, NT-175, TSC 101, SCG 162, TAC01 HER2, ECT204, TSC-100, IMA201, CMV TCR-T, 820 TCR, MAGE-A4 TCR program, and others.

To dive deep into rich insights for drugs used for TCR Therapy treatment, visit: https://www.delveinsight.com/report-store/tcr-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. TCR Therapy Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. TCR Therapy Pipeline Therapeutics
6. TCR Therapy Pipeline: Late-Stage Products (Phase III)
7. TCR Therapy Pipeline: Mid-Stage Products (Phase II)
8. TCR Therapy Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.